| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Center, University of Rochester, Rochester, New York 14642 [E. M. L., L. H.], and Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6072
2 To whom requests for reprints should be addressed.
Hypoxic cells in tissue pose many medical problems, and there is a need for more accurate measurements of tissue hypoxia. However, measurement of the pO2 and the extent of hypoxia within normal and tumor tissue have proven difficult. One of the most sensitive of the currently available methodologies involves the oxygen-dependent metabolic activation of nitroheterocyclic drugs, leading to adducts between the drugs and cellular macromolecules. Limitations of the present drugs and adduct-detection methods prompted the present studies. A pentafluorinated derivative [EF5; 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3-pentafluoropropyl)acetamide] of etanidazole was synthesized with the expectation of lessening some of the non-oxygen-dependent variability in adduct formation observed previously with other nitroaromatic compounds. EF5-protein conjugates, prepared by radiochemical reduction, were found to be immunogenic and allowed the development of monoclonal antibodies. One of these antibodies, ELK2-4, has been characterized and found to be highly specific for the EF5 adducts whether produced radiochemically or by cellular bioreductive metabolism. 9L rat glioma cells pretreated with EF5 under hypoxic, compared with aerobic, conditions were readily discriminated immunochemically using fluorochrome-conjugated secondary antibodies which recognize the ELK2-4 antibody subtype (IgG1). Similarly, the central region of multicellular spheroids, composed of EMT6 mouse mammary sarcoma cells, was selectively visualized by immunohistochemistry after the spheroids were incubated for 4 h in 0.5 mM EF5. Tumor biopsy, preparation, and immunohistochemical staining 24 h after treatment of tumor-bearing animals with drug also demonstrated high contrast regions within EMT6 mouse or Morris 7777 hepatoma rat tumors. The use of this new compound and its highly specific monoclonal antibody may allow elucidation of bioreductive metabolism of the nitroheterocyclics and significantly improve technologies for the quantitation of tissue pO2.
1 Work partially supported by Grant CA28332 (E. M. L.) from the National Cancer Institute and Grant DHP-27B (C. J. K.) from the American Cancer Society.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 5/24/93. Accepted 9/30/93.
This article has been cited by other articles:
|
|
 |
|
  J. Ma and D. J. Waxman Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib Clin. Cancer Res., January 15, 2009; 15(2): 578 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.E. Baker, J. Lam, A. H. Kyle, J. Sy, T. Oliver, S. J. Co, W. H. Dragowska, E. Ramsay, M. Anantha, T. J. Ruth, et al. Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin Clin. Cancer Res., November 15, 2008; 14(22): 7260 - 7271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. He, X. Deng, B. Wen, Y. Liu, X. Sun, L. Xing, A. Minami, Y. Huang, Q. Chen, P. B. Zanzonico, et al. Noninvasive Molecular Imaging of Hypoxia in Human Xenografts: Comparing Hypoxia-Induced Gene Expression with Endogenous and Exogenous Hypoxia Markers Cancer Res., October 15, 2008; 68(20): 8597 - 8606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Ream, R. Chandra, M. Peavey, A. M. Ray, S. Roffler-Tarlov, H.-G. Kim, W. C. Wetsel, H. A. Rockman, and D. M. Chikaraishi High oxygen prevents fetal lethality due to lack of catecholamines Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R942 - R953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wang, R. C. Scott, C. B. Pattillo, B. Prabhakarpandian, S. Sundaram, and M. F. Kiani Microvascular transport model predicts oxygenation changes in the infarcted heart after treatment Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3732 - H3739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Fenton and S. F. Paoni The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature Cancer Res., October 15, 2007; 67(20): 9921 - 9928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad, K. Galappathi, B. Mathiesen, and E.-B. M. Ruud Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis Clin. Cancer Res., April 1, 2007; 13(7): 1971 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gerber, V. Y. Rybalko, C. E. Bigelow, A. A. Lugade, T. H. Foster, J. G. Frelinger, and E. M. Lord Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth Am. J. Pathol., November 1, 2006; 169(5): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kaper, N. Dornhoefer, and A. J. Giaccia Mutations in the PI3K/PTEN/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic Conditions Cancer Res., February 1, 2006; 66(3): 1561 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Koshikawa and K. Takenaga Hypoxia-Regulated Expression of Attenuated Diphtheria Toxin A Fused with Hypoxia-Inducible Factor-1{alpha} Oxygen-Dependent Degradation Domain Preferentially Induces Apoptosis of Hypoxic Cells in Solid Tumor Cancer Res., December 15, 2005; 65(24): 11622 - 11630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mackay, D. Hedley, P. Major, C. Townsley, M. Mackenzie, M. Vincent, P. Degendorfer, M.-S. Tsao, T. Nicklee, D. Birle, et al. A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5526 - 5533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wang, R. Ansari, Y. Sun, A. E. Postlethwaite, K. T. Weber, and M. F. Kiani The scar neovasculature after myocardial infarction in rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H108 - H113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Ziemer, W. M. F. Lee, S. A. Vinogradov, C. Sehgal, and D. F. Wilson Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence J Appl Physiol, April 1, 2005; 98(4): 1503 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Fenton, S. F. Paoni, and I. Ding Pathophysiological Effects of Vascular Endothelial Growth Factor Receptor-2-Blocking Antibody plus Fractionated Radiotherapy on Murine Mammary Tumors Cancer Res., August 15, 2004; 64(16): 5712 - 5719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Laakkonen, M. E. Akerman, H. Biliran, M. Yang, F. Ferrer, T. Karpanen, R. M. Hoffman, and E. Ruoslahti Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells PNAS, June 22, 2004; 101(25): 9381 - 9386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hedley, M. Pintilie, J. Woo, A. Morrison, D. Birle, A. Fyles, M. Milosevic, and R. Hill Carbonic Anhydrase IX Expression, Hypoxia, and Prognosis in Patients with Uterine Cervical Carcinomas Clin. Cancer Res., November 15, 2003; 9(15): 5666 - 5674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zheng, C. Wasylyk, A. Ayadi, J. Abecassis, J. A Schalken, H. Rogatsch, N. Wernert, S.-M. Maira, M.-C. Multon, and B. Wasylyk The transcription factor Net regulates the angiogenic switch Genes & Dev., September 15, 2003; 17(18): 2283 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Seddon, R. J. Maxwell, D. J. Honess, R. Grimshaw, F. Raynaud, G. M. Tozer, and P. Workman Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy Clin. Cancer Res., July 1, 2002; 8(7): 2323 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Yu, J. W. Rak, B. L. Coomber, D. J. Hicklin, and R. S. Kerbel Effect of p53 Status on Tumor Response to Antiangiogenic Therapy Science, February 22, 2002; 295(5559): 1526 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schipani, H. E. Ryan, S. Didrickson, T. Kobayashi, M. Knight, and R. S. Johnson Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival Genes & Dev., November 1, 2001; 15(21): 2865 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Vukovic, H. K. Haugland, T. Nicklee, A. J. Morrison, and D. W. Hedley Hypoxia-inducible Factor-1{alpha} Is an Intrinsic Marker for Hypoxia in Cervical Cancer Xenografts Cancer Res., October 1, 2001; 61(20): 7394 - 7398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Hunter, D. Yu, M. Gee, C. V. Ngo, C. Sevignani, M. Goldschmidt, T. V. Golovkina, S. Evans, W. F. Lee, and A. Thomas-Tikhonenko Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis J. Immunol., May 15, 2001; 166(10): 5878 - 5881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hockel and P. Vaupel Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects J Natl Cancer Inst, February 21, 2001; 93(4): 266 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ding, J. Z. Sun, B. Fenton, W. M. Liu, P. Kimsely, P. Okunieff, and W. Min Intratumoral Administration of Endostatin Plasmid Inhibits Vascular Growth and Perfusion in MCa-4 Murine Mammary Carcinomas Cancer Res., January 1, 2001; 61(2): 526 - 531. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. S. Wan, L.-J. W. Lu, K. E. Anderson, J. H. Ware, and A. R. Kennedy Urinary Excretion of Bowman-Birk Inhibitor in Humans after Soy Consumption as Determined by a Monoclonal Antibody-based Immunoassay Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 741 - 747. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kajino, Y.-Q. Chen, S. Chemtob, N. Waleh, C. J. Koch, and R. I. Clyman Tissue hypoxia inhibits prostaglandin and nitric oxide production and prevents ductus arteriosus reopening Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2000; 279(1): R278 - R286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Koong, N. C. Denko, K. M. Hudson, C. Schindler, L. Swiersz, C. Koch, S. Evans, H. Ibrahim, Q. T. Le, D. J. Terris, et al. Candidate Genes for the Hypoxic Tumor Phenotype Cancer Res., February 1, 2000; 60(4): 883 - 887. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Gee, C. J. Koch, S. M. Evans, W. T. Jenkins, C. H. Pletcher Jr., J. S. Moore, H. K. Koblish, J. Lee, E. M. Lord, G. Trinchieri, et al. Hypoxia-mediated Apoptosis from Angiogenesis Inhibition Underlies Tumor Control by Recombinant Interleukin 12 Cancer Res., October 1, 1999; 59(19): 4882 - 4889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grunstein, W. G. Roberts, O. Mathieu-Costello, D. Hanahan, and R. S. Johnson Tumor-derived Expression of Vascular Endothelial Growth Factor Is a Critical Factor in Tumor Expansion and Vascular Function Cancer Res., April 1, 1999; 59(7): 1592 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Mueller-Klieser Three-dimensional cell cultures: from molecular mechanisms to clinical applications Am J Physiol Cell Physiol, October 1, 1997; 273(4): C1109 - C1123. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
